Benign Prostatic Hyperplasia: Which Treatment Fits My Case

Choosing a treatment is not a simple question of "which technique is better," but an assessment of several factors together. The following areas usually guide the discussion — they are not a rigid algorithm that automatically produces a result.

• Symptom severity — how much frequency, nocturia, or difficulty urinating affects daily life
• Obstruction findings — uroflowmetry (urine flow rate) results and post-void residual urine measurement
• Prostate size and anatomy — total volume, but also the presence of a median lobe or other anatomical features
• Coexisting conditions and medication — blood thinners or antiplatelet drugs, cardiovascular history, previous pelvic surgery
• The patient's personal priorities — how important preserving ejaculation is to you, how quickly you want to recover, and your attitude toward the possibility of needing a future re-treatment

Each of these factors is discussed individually with your urologist before you settle on a technique.

Many patients confuse "simple prostatectomy" (a BPH treatment) with "radical prostatectomy" (a prostate cancer treatment) — the two terms sound similar but refer to entirely different conditions and operations.

In simple prostatectomy (robotic or 3D laparoscopic), only the inner, hyperplastic tissue causing the obstruction is removed — the peripheral gland stays in place, exactly as with HoLEP, laser enucleation. In radical prostatectomy, the entire prostate gland is removed together with the seminal vesicles, because the goal is treating cancer, not obstruction.

If your concern is a recent prostate cancer diagnosis rather than obstructive BPH symptoms, our prostate cancer diagnosis decoder guide is likely more relevant to you than this article.

HoLEP (Holmium Laser Enucleation of the Prostate) is an endoscopic enucleation technique in which the entire hyperplastic tissue is removed through the urethra, without an external incision, and then morcellated and removed from the bladder. Because it removes essentially all of the hyperplastic tissue — a similar principle to open or robotic/laparoscopic simple prostatectomy, but through an endoscopic approach — it has been specifically studied even in very large prostates, where other endoscopic techniques may have limitations. The removed tissue is always sent for histological examination, which provides additional information. More details, indications, and what to expect are on the HoLEP page.

Rezūm uses controlled doses of water vapor injected locally into the hyperplastic tissue, causing its gradual destruction and reabsorption over the following weeks. Because it does not remove tissue immediately during surgery, the final improvement in urine flow often appears gradually rather than right away. It is generally considered one of the less invasive options, which is why it is often discussed for patients who place particular value on a short procedure time, although its suitability also depends on prostate size and anatomy. See the Rezūm page for more.

For particularly enlarged prostates, where the treating urologist judges that an endoscopic technique is not the most suitable option, surgical simple prostatectomy through small abdominal incisions remains an established alternative. Both approaches — robotic and 3D laparoscopic — follow the same basic surgical principle: removing the hyperplastic tissue while preserving the peripheral gland, through minimally invasive access rather than an open incision.

The difference between them mainly concerns the tool the surgeon uses — a robotic system or classic laparoscopic instruments with three-dimensional imaging — rather than a different goal or outcome of the procedure. The choice between them usually depends on equipment availability and the surgical center's familiarity with one approach or the other. See the 3D laparoscopic prostate adenomectomy in detail.

The length of hospital stay, the duration the urinary catheter stays in, and the pace of returning to daily activities differ by technique, but also by the individual patient — there is no single timeline that applies precisely to everyone.

• Endoscopic techniques (HoLEP, Aquablation, TURiS) are done without an external incision and usually involve a short hospital stay, with the catheter removed within the first few days, depending on the clinical picture
• Rezūm is often done as a short-stay or same-day procedure, with the catheter remaining for a period determined by the surgeon
• Robotic and 3D laparoscopic simple prostatectomy involve abdominal incisions (even if small) and usually mean a longer hospital stay and catheter duration compared to purely endoscopic techniques

The exact timeline in your case is determined by your surgeon based on your healing progress, not by a general rule.

The following examples are purely educational and are not a treatment recommendation for any real patient — their purpose is to show how the factors described above combine differently in each case.

• Patient A, 58, prostate ~45 mL: Moderate symptoms, no significant medical history. Their discussion will mainly focus on symptom severity and personal priorities, since the size does not place particular limits on any technique
• Patient B, 72, prostate ~110 mL, on blood thinners: Here, the blood-thinning medication and larger size will be central discussion points, as they affect both the choice of technique and the timing of stopping or adjusting the medication
• Patient C, 65, prostate ~70 mL, prioritizes preserving ejaculation: Their personal priority will lead to a specific discussion about the risk of retrograde ejaculation by technique
• Patient D, 68, very large prostate, without significant symptom severity yet: Here the discussion will focus on whether and when intervention is needed, not only on which technique

In none of these cases is there a single "correct" answer without a full clinical evaluation.

Before any treatment discussion, a basic diagnostic evaluation is needed that objectively documents the severity of the obstruction and rules out other causes of symptoms.

• Uroflowmetry and post-void residual measurement — an objective recording of urine flow and the residual amount after voiding
• PSA test — a test that helps rule out coexisting prostate cancer
• Urodynamic study — in selected, more complex cases, when a more detailed assessment of bladder function is needed

The findings of these tests, combined with the clinical examination, form the basis on which each technique is realistically discussed.

If you are facing a treatment decision for benign prostatic hyperplasia and want to discuss your options based on your own findings, Dr. Marinos Vasilas sees patients in Rhodes for clinical evaluation, review of previous test results, and, where needed, guidance toward the appropriate further work-up or referral. A face-to-face conversation, with your own data on the table, remains more useful than any general guide — including this one.